Growth Metrics

Bioadaptives (BDPT) Cost of Revenue (2016 - 2025)

Bioadaptives' Cost of Revenue history spans 7 years, with the latest figure at $2844.0 for Q4 2025.

  • On a quarterly basis, Cost of Revenue changed N/A to $2844.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $5781.0, a 33.08% decrease, with the full-year FY2025 number at $5781.0, down 33.08% from a year prior.
  • Cost of Revenue hit $2844.0 in Q4 2025 for Bioadaptives, up from $781.0 in the prior quarter.
  • Over the last five years, Cost of Revenue for BDPT hit a ceiling of $10999.0 in Q3 2023 and a floor of $246.0 in Q2 2024.
  • Historically, Cost of Revenue has averaged $3052.2 across 5 years, with a median of $2227.0 in 2021.
  • Biggest five-year swings in Cost of Revenue: tumbled 71.02% in 2024 and later soared 776.42% in 2025.
  • Tracing BDPT's Cost of Revenue over 5 years: stood at $2709.0 in 2021, then grew by 9.04% to $2954.0 in 2022, then soared by 52.4% to $4502.0 in 2023, then tumbled by 94.54% to $246.0 in 2024, then soared by 1056.1% to $2844.0 in 2025.
  • Business Quant data shows Cost of Revenue for BDPT at $2844.0 in Q4 2025, $781.0 in Q3 2025, and $2156.0 in Q2 2025.